|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||64.15 - 65.22|
|52-week range||56.56 - 85.79|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||662.14|
|Earnings date||28 Apr 2021 - 03 May 2021|
|Forward dividend & yield||2.84 (4.39%)|
|Ex-dividend date||12 Mar 2021|
|1y target est||74.88|
Moderna shares surge after U.S. regulators put a pause on the use of Johnson & Johnson's COVID-19 vaccine. Hartaj Singh, Oppenheimer Analyst joins Yahoo Finance Live to weigh in on the outlook for the biotech industry.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study. Of the 112 patients who were evaluable for efficacy, 27.7% of those treated with Trodelvy responded to treatment, with 5.4% experiencing a complete response and 22.3% experiencing a partial response. The median duration of response was 7.2 months (95% CI: 4.7-8.6). The Trodelvy U.S. Prescribing Information has a BOXED WARNING for severe or life-threatening neutropenia and severe diarrhea; see below for Important Safety Information.
Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.